Previous Page  23 / 25 Next Page
Information
Show Menu
Previous Page 23 / 25 Next Page
Page Background

Page 67

Mater Sci Nanotechnol 2017 | Volume 1 Issue 2

allied

academies

Nanomaterials and Nanochemistry

November 29-30, 2017 | Atlanta, USA

International Conference on

D

espite the success erlotinib achieved in fighting lung

cancers, the problems of grading and monitoring the

tumor as well as predicting the treatment response may

result in failure of the therapy and resistance of the tumor,

which requires the use of a suitable diagnostic tool that

can monitor the treatment and predicting the treatment

response. As an attempt to address such problems, we

designed a novel theranostic nanoparticle formulation

(NPs) of superparamagnetic iron oxide core, coated with a

thin dextran layer (as determined by transmission electron

microscope (TEM) imaging and dynamic light scattering)

and linked to erlotinib. Such NPs are smart, targeting cancer

cells that overexpress the EGFR, releasing the active drug

intracellularly rather than in the blood stream, accumulating

inside the cancer cells producing high contrast in themagnetic

resonance imaging (MRI) and being non-toxic to the EGFR-

negative cells. Cellular uptake of the NPs was higher than the

product used commonly in clinical practice as MRI contrast

agent, this was evident from the MRI, TEM and Prussian

blue imaging results. Furthermore, we tested the molecular

mechanisms that may account for the potent activity of our

NPs and found that the NPs inhibited the phosphorylation of

the overexpressed EGFR as well as the oncogenic signaling

pathways downstream of the EGFR such as the ERK and

NF-κB pathways which was confirmed by Western blotting

and confocal immunocytochemical imaging. Moreover, the

T2-weighted MRI images of the BALB/c nude mice showed

significant decrease in the normalized signal within the

tumor post-treatment with the NPs compared to the non-

targeted control iron oxide nanoparticles.

e:

ahmedatf@yahoo.com

Smart targeted erlotinib-SPION nanoparticles for MRI applications

Ahmed Atef Ahmed Ali

Institute of Molecular Biology Academia Sinica, Taiwan